Evidence map›Paper›PMID 35409173›Full record

ArticleInternational journal of molecular sciences2022

Identification of Tumor-Suppressive

Chikashi Minemura, Shunichi Asai, Ayaka Koma, Ikuko Kase-Kato, Nozomi Tanaka, Naoko Kikkawa, Atsushi Kasamatsu, Hidetaka Yokoe, Toyoyuki Hanazawa, Katsuhiro Uzawa and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chikashi MinemuraDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.ORCID 0000-0001-8539-6240
Shunichi AsaiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Ayaka KomaDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Ikuko Kase-KatoDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Nozomi TanakaDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Naoko KikkawaDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Atsushi KasamatsuDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.ORCID 0000-0002-8054-2584
Hidetaka YokoeDepartment of Oral and Maxillofacial Surgery, National Defense Medical College Hospital, Tokorozawa 359-8513, Japan.
Toyoyuki HanazawaDepartment of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0000-0001-9721-5662
Katsuhiro UzawaDepartment of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.ORCID 0000-0002-7036-0859
Naohiko SekiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0000-0003-4731-7956
Chiba University · JPNational Defense Medical College Hospital · JP

Funding

JSPS KAKENHI 19H03847JSPS KAKENHI 20H03883JSPS KAKENHI 21K09577
6 · The paper itself

Abstract

Recently, our studies revealed that some passenger strands of microRNAs (miRNAs) were closely involved in cancer pathogenesis. Analysis of miRNA expression signatures showed that the expression of miR-30e-3p (the passenger strand of pre-miR-30e) was significantly downregulated in cancer tissues. In this study, we focused on miR-30e-3p (the passenger strand of pre-miR-30e). We addressed target genes controlled by miR-30e-3p that were closely associated with the molecular pathogenesis of head and neck squamous cell carcinoma (HNSCC). Ectopic expression assays demonstrated that the expression of miR-30e-3p attenuated cancer cell malignant phenotypes (e.g., cell proliferation, migration, and invasive abilities). Our analysis of miR-30e-3p targets revealed that 11 genes (ADA, CPNE8, C14orf126, ERGIC2, HMGA2, PLS3, PSMD10, RALB, SERPINE1, SFXN1, and TMEM87B) were expressed at high levels in HNSCC patients. Moreover, they significantly predicted the short survival of HNSCC patients based on 5-year overall survival rates (p < 0.05) in The Cancer Genome Atlas (TCGA). Among these targets, SERPINE1 was found to be an independent prognostic factor for patient survival (multivariate Cox regression; hazard ratio = 1.6078, p < 0.05). Aberrant expression of SERPINE1 was observed in HNSCC clinical samples by immunohistochemical analysis. Functional assays by targeting SERPINE1 expression revealed that the malignant phenotypes (e.g., proliferation, migration, and invasion abilities) of HNSCC cells were suppressed by the silencing of SERPINE1 expression. Our miRNA-based approach will accelerate our understanding of the molecular pathogenesis of HNSCC.

Indexed as

Head and Neck NeoplasmsMicroRNAsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansPlasminogen Activator Inhibitor 1Proteasome Endopeptidase ComplexProto-Oncogene ProteinsSquamous Cell Carcinoma of Head and NeckCarrier ProteinsCPNE8 protein, humanMicroRNAsPlasminogen Activator Inhibitor 1Proteasome Endopeptidase ComplexProto-Oncogene ProteinsPSMD10 protein, humanSERPINE1 protein, humanHNSCCmicroRNAmiR-30e-3pSERPINE1TCGAtumor suppressor

Identifiers

PMID35409173
PMCPMC8998321
OpenAlexW4220932987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.